The meta-analysis included 17 cohorts involving a total of 185 530 patients with IMIDs (33 681 treated with JAK inhibitors vs 151 849 treated with TNF antagonists), with 3467 case patients with malignant neoplasms.20,23,26,28,34,36,37,38,39,40,41,42,45The IR of malignant neoplasms was 1.00 (95% CI, 0.77-1.31) per 100 person-years with JAK inhibitors vs 0.94 (95% CI, 0.72-1.22) per 100 person-years with TNF antagonists. This evidence concerns the gene TNF and cancer.